Osteoporosis Drugs Cut Dementia Risk 16% in 120,000-Patient Study
Updated
Updated · SciTechDaily · Sep 15
Osteoporosis Drugs Cut Dementia Risk 16% in 120,000-Patient Study
2 articles · Updated · SciTechDaily · Sep 15
Summary
Nitrogen-containing bisphosphonates were linked to a 16% lower risk of Alzheimer’s disease and related dementias versus no treatment in adults 60 and older with osteoporosis or fragility fractures.
The University of Hong Kong team analyzed citywide electronic records from 2005 to 2020 and found NBP users also had a 24% lower dementia risk than patients taking other osteoporosis drugs.
The association was strongest in women and people with hip fractures, and the researchers estimated treating 48 patients for five years could prevent one dementia case.
NBPs such as alendronate and zoledronate are already widely used to strengthen bones, making them candidates for repurposing as dementia prevention is sought for aging populations.
More than 55 million people live with dementia worldwide, a figure projected to reach 139 million by 2050, underscoring interest in cheaper preventive options than newer Alzheimer’s therapies.